Verici Dx logo

VRCI - Verici Dx News Story

48p -0.5  -1.0%

Last Trade - 21/01/22

Sector
Healthcare
Size
Small Cap
Market Cap £68.0m
Enterprise Value £68.1m
Revenue £n/a
Position in Universe th / 1804

RCS - Verici Dx PLC - Launch of Barbara T. Murphy Endowed Lectureship

Mon 8th November, 2021 7:00am
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211108:nRSH6279Ra&default-theme=true

RNS Number : 6279R  Verici Dx PLC  08 November 2021

Verici Dx plc

("Verici Dx" or the "Company")

 

Launch of Barbara T. Murphy Endowed Lectureship

 

Launch of lecture commemorating Verici Dx co-founder and former Board
member with American Society of Nephrology supported by Verici Dx Plc,
Renalytix plc and in conjunction with the American Society of Transplantation,
starting at ASN Kidney Week 2022

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, announces that it has signed an agreement with Renalytix plc
(NASDAQ: RLNX AIM: RENX) and the American Society of Transplantation ("AST"),
to establish and sponsor collectively the Barbara T. Murphy Endowed
Lectureship ("The Murphy Lectureship"), commemorating Dr. Barbara T. Murphy,
Verici Dx's late co-founder and Board member.  Under the Murphy Lectureship,
a lecture will be given each year in perpetuity during the American Society of
Nephrology ("ASN") Kidney Week.  Dr. Murphy was also a co-founder and Board
member of Renalytix plc and a long serving member of the ASN, on whose Council
she served and of which she was President-Elect; she was also a former
president of the AST and former co-chair of its Public Policy committee.

 

The lectureship, which will begin at ASN Kidney Week being held in November
2022, will honour Dr. Murphy's legacy as a renowned leader in transplant
immunology and medicine by recognising advances in kidney transplantation.

 

Each lecture will feature a significant figure in kidney transplant immunology
and medicine, focusing on kidney risk pre-transplant and transplant care. The
lecturers may be physicians, scientists, or represent any other discipline
provided they meet the award criteria.  During her career, Dr. Murphy
catalysed considerable activity across multiple centers of excellence and this
collaborative approach generated a significant body of insights into the
immunological mechanisms involved in transplant rejection and the scope for
improving transplant care.  The Murphy Lectureship in her honour is intended
to foster continuing co-operation across different fields of expertise in
support of further patient gains in transplant medicine and care.

 

Sara Barrington, CEO of Verici Dx, said: "We are proud and honoured to be able
to sponsor and establish The Murphy Lectureship alongside ASN, Renalytix and
the AST at ASN Kidney Week. It is a fitting tribute to Barbara as a former
friend, colleague and inspirational leading nephrologist and specialist in
kidney transplant immunology.

 

"Verici Dx is committed to following Barbara's vision of improving patient
outcomes and is on track to complete the clinical validation trial for the
assessment of pre-transplant risk and the measurement of post-transplant
rejection tests at the end of 2021."

 

About Dr. Barbara T. Murphy

 

While attending medical school at the Royal College of Surgeons in Ireland,
Dr. Murphy was inspired to pursue a career in treating and researching kidney
diseases and transplant immunology by a young dialysis patient who received a
second chance at life after a successful kidney transplant. This passion led
Dr. Murphy to the United States, where she completed a nephrology fellowship
at Harvard Medical School's Brigham and Women's Hospital in Boston,
Massachusetts.

 

Dr. Murphy served as the Chair of the Department of Medicine from 2012 - 2021
at the Icahn School of Medicine at Mount Sinai, was the first female Chair of
a Department of Medicine at an academic medical center in New York City and,
at the time, was only the second female Chair of any Department at a top 20
medical school in the United States.  She was the Dean for Strategy and
Innovation and the Murray M. Rosenberg Professor of Medicine at the Icahn
School of Medicine at Mount Sinai, and held a variety of leadership roles in
national and international organisations, including AST President and ASN
President-Elect at the time of her passing earlier this year.

 

Among Dr. Murphy's many honours, she was named Nephrologist of the Year in
2011 by the American Kidney Fund, included in the Irish American "Healthcare
and Life Science 50" in 2016, and identified as one of Crain's New York's
"Notable Women in Health Care" in 2018. She received numerous honorary
doctoral degrees from universities and medical schools.

 

Dr. Murphy was also the inaugural recipient of ASN's new lifetime achievement
Trailblazer Award. ASN launched the award in 2021 to honour leaders who
strengthen the foundation of nephrology while advancing the field through
innovation, creativity, inspiration, and tenacity.

 

 

Enquiries:

 

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     Via Walbrook PR
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: 020 7496 3000
 Aubrey Powell / Kailey Aliyar / Tom Salvesen

 Walbrook PR Limited                                      Tel: 020 7933 8780 or vericidx@walbrookpr.com
                                                          (mailto:renalytix@walbrookpr.com)
 Paul McManus / Sam Allen                                 Mob: 07980 541 893 / 07502 558 258

 

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

Verici Dx is an immuno-diagnostics company developing and commercialising
tests to understand how a patient will respond and is responding to organ
transplant, with an initial focus on kidney transplants. The body's own immune
system poses a threat to a successful transplant or graft. Patients' immune
systems differ in how they respond to the presence of the transplanted
organ.  Characterising this response and those of other biological pathways
enables the development of RNA signatures for prognostic and diagnostic tests.
Our products and solutions are underpinned by extensive scientific research
into the recipient's RNA signatures and how that impacts on acute rejection,
chronic injury and ultimately failure of the transplant. These RNA signatures
may also inform clinicians as to the optimal strategy for immunosuppressive
and other therapies for the most successful treatment to ensure graft
acceptance with the least amount of side effects.

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

The organ transplant diagnostics described above are based on technology
developed by Mount Sinai faculty and licensed to Verici Dx. Mount Sinai has a
financial interest in Verici Dx. Mount Sinai also has representation on the
Verici Dx Board of Directors.

 

About The American Society of Nephrology

 

Since 1966, ASN has been creating a world without kidney diseases by educating
and informing, driving breakthroughs and innovation, and advocating for
policies that create transformative changes in kidney medicine throughout the
world. ASN has more than 21,000 members representing 131 countries. For more
information, visit www.asn-online.org (http://www.asn-online.org/) .

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABPBFTMTAMMFB
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.